Advances in Immunopharmacology

1st Edition, Volume 91 - June 5, 2021
Editors: Cheryl Rockwell, Bryan Copple
Language: English
Hardback ISBN:
9 7 8 - 0 - 1 2 - 8 2 3 5 6 2 - 1
eBook ISBN:
9 7 8 - 0 - 1 2 - 8 2 3 5 6 3 - 8

Advances in Pharmacology, Volume 91, the latest release in this well-received series, presents the latest information in the field, with this update including chapters on Modula… Read more

Purchase options

Institutional subscription on ScienceDirect

Request a sales quote

Advances in Pharmacology, Volume 91, the latest release in this well-received series, presents the latest information in the field, with this update including chapters on Modulation of inflammation and immune response by the stress-activated transcription factor Nrf2, Therapeutic modulation of macrophage phenotype to treat acute and chronic liver diseases, Immodulation by cannabinoids, The use of nanomaterials to target immunity, Next generation in cancer immunotherapy, checkpoint inhibitors, Vaccines as a therapy for food allergy, Role of inflammation/immune system in depression, Therapeutic targeting of tumor-associated macrophages, Mast cells, and more.

Cover image
Title page
Table of Contents
Copyright
Contributors
Preface
Chapter One: Immunomodulation by cannabinoids: Current uses, mechanisms, and identification of data gaps to be addressed for additional therapeutic application
Abstract
1: Introduction
2: Discovery of the endocannabinoid system
3: Plant-derived and synthetic cannabinoid ligands
4: Current cannabinoid pharmaceuticals
5: Cannabinoid-mediated alterations in intracellular signaling in immune cells
6: Evidence for cannabinoid efficacy in immune-mediated diseases
7: Conclusion
Acknowledgments
COI statement
Chapter Two: The role of Nrf2 in autoimmunity and infectious disease: Therapeutic possibilities
Abstract
1: Introduction
2: Nrf2 as a therapeutic target for autoimmune disorders
3: Nrf2 as a therapeutic target for infectious diseases
4: Conclusion
Conflict of interest statement
Chapter Three: Review of immune checkpoint inhibitors in immuno-oncology
Abstract
1: Introduction
2: Co-stimulatory and co-inhibitory molecules: Exploiting checks and balances in the immune system
3: Mechanisms of ICI failure in tumors
4: Immune-related adverse events (irAEs)
5: The future of tumor immunotherapy
6: Conclusion
Acknowledgment
Conflict of interest
Chapter Four: Potential therapeutic uses of rexinoids
Abstract
1: Introduction
2: RXR and the immune system in vitro
3: RXR agonists (rexinoids)
4: Preclinical studies with rexinoids
5: Clinical studies
6: Future directions
7: Conclusion
Acknowledgments
Conflict of interest statement
Chapter Five: Therapeutic targeting of tumor-associated macrophages
Abstract
1: Introduction
2: Heterogeneity and function of tumor-associated macrophages
3: Therapeutic targeting of TAM
4: Conclusion
Acknowledgments
Conflict of interest
Chapter Six: Modulation of macrophage phenotype to treat liver fibrosis—Current approaches and future possibilities
Abstract
1: Introduction
2: Phenotypic characteristics of proinflammatory monocytes and pro-resolving macrophages in fibrosis development and reversal
3: Nanomedicine
4: High-throughput phenotypic drug screening
5: Stem cell-based therapies
6: Conclusion
Conflict of interest
Chapter Seven: Vaccines as therapies for food allergies
Abstract
1: Introduction
2: Allergen-specific immunotherapy
3: Modified hypoallergenic proteins for the treatment of food allergy
4: mRNA and DNA vaccines
5: Adjuvants
6: Nanoparticle vaccine delivery systems and adjuvants
7: Conclusion
Conflict of interest
Chapter Eight: Neuroimmunology of depression
Abstract
1: Introduction
2: Immune disorders comorbid with depression
3: CNS immunity
4: Immune cells in the meninges
5: Connecting meningeal immunity to depression
6: Immune cells in the brain
7: Glial degeneration and depression
8: Neuroinflammation and proposed mechanisms of depression
9: Antidepressants and the immune system
10: Conclusion: Immunomodulatory drugs, a new class of antidepressant therapies?
Chapter Nine: Nanomaterials to target immunity
Abstract
1: Introduction
2: Nanoimmuno-engineering principles
3: Nanoimmunotherapy applications
4: Nanoimmunotherapy translation
5: Toxicology of nanoimmunotherapies
6: Conclusion
Acknowledgments
Conflict of interest

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

Advances in Immunopharmacology

Purchase options

Institutional subscription on ScienceDirect

Cheryl Rockwell

Bryan Copple